The bright prospects for cancer drug Erbitux are a focal point in Bristol-Myers Squibb’s bid to acquire ImClone. But just as important in the long run may be Erbitux’s successor, still in development.
Just how much better would Erbitux II be? The answer to that question matters because the experimental medicine is at the center of [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment